CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) - USD ($) $ in Thousands		9 Months Ended
		Sep. 30, 2025	Sep. 30, 2024
Cash flows from operating activities:
Net loss		$ (57,458)	$ (64,859)
Adjustments to reconcile net loss to net cash used in operating activities
Stock-based compensation expense		7,131	8,017
Depreciation and amortization		7,584	8,398
Noncash operating lease cost		1,204	1,036
Amortization of discount on short-term investments		(3,146)	(1,826)
Other		(229)	56
Changes in operating assets and liabilities
Accounts receivable	[1]	(6,236)	4,255
Inventory and other deferred costs		1,284	1,979
Prepaid expenses and other assets		(1,275)	271
Accounts payable	[2]	2,731	(4,135)
Accrued and other current liabilities	[2]	524	(3,161)
Contract liabilities		(1,644)	(3,638)
Operating lease liabilities		(3,020)	(2,571)
Other long-term liabilities	[2]	(150)	550
Net cash used in operating activities		(52,700)	(37,354)
Cash flows from investing activities:
Purchases of available-for-sale debt securities		(156,447)	(76,769)
Proceeds from maturities of available-for-sale debt securities		152,685	68,000
Purchases of property and equipment		(4,427)	(357)
Proceeds from sales of property and equipment			240
Net cash used in investing activities		(8,189)	(8,886)
Cash flows from financing activities:
Proceeds from sales of common stock under ATM facility, net of commissions		17,782	30,079
Proceeds from exercise of Tempus Warrants			18,438
Proceeds from sale of common stock under Tempus Investment Agreement			17,745
Payment of costs related to Tempus and Merck Investment Agreements		(106)	(800)
Proceeds from loans		2,587
Repayments of loans		(1,718)	(822)
Proceeds from issuance of common stock under equity incentive plans		898	431
Net cash provided by financing activities		19,443	65,071
Effect of exchange rates on cash, cash equivalents and restricted cash		4	(15)
Net change in cash, cash equivalents and restricted cash		(41,442)	18,816
Cash, cash equivalents and restricted cash, beginning of period		93,205	58,774
Cash, cash equivalents and restricted cash, end of period		51,763	77,590
Reconciliation of cash, cash equivalents and restricted cash to the consolidated balance sheets:
Cash and cash equivalents		49,973	75,800
Restricted cash, included in other long-term assets		1,790	1,790
Total cash, cash equivalents and restricted cash		51,763	77,590
Supplemental cash flow information:
Acquisition of property and equipment included in accounts payable and accrued liabilities		2,523	1,010
Right-of-use finance lease assets obtained in exchange for finance lease liabilities		$ 3,153
Tempus Warrants
Adjustments to reconcile net loss to net cash used in operating activities
Noncash gain related to liability classified Tempus Warrants			$ 18,274

[1] Includes a change in related party receivable of $0.1 million for the nine months ended September 30, 2025.

[2] Includes a change in related party liabilities of $2.7 million for the nine months ended September 30, 2025.